ptsd
- Home
- ptsd
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
Biotechnology company Emyria (ASX: EMD), which develops treatments for mental health and neurological conditions, has newly inaugurated its treatment facility Empax Centre. The centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics. The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen
Read MorePublic
Vitura’s Cortexa becomes first Aus company to supply ecstasy and magic mushrooms under TGA’s prescriber scheme
In July last year, Australia became the first country to legalise ecstasy (MDMA) and magic mushrooms (psilocybin) for mental health disorders, including PTSD and depression. A bold move, it spurred medical businesses into action, seeking the proper approvals and getting the early advantage. At the same time, not all medical professionals were so thrilled, citing
Read MorePublic
TGA gives green light to Emyria’s psychiatrists for MDMA therapy for PTSD
Mental health treatment provider Emyria (ASX: EMD) has announced that its psychiatry specialist has been granted “Authorised Prescriber” status by the Therapeutic Goods Administration (TGA). The authorisation enables the prescribing of MDMA according to an ethics committee endorsed care model developed by Emyria and within the strict regulatory framework established by the TGA for the
Read MorePublic
Melodiol reports positive results from Halucenex trials for magic mushrooms to treat PTSD
In Australia, about 43% of people aged between 16 and 85 had experienced a mental disorder at some point as of 2023. Between 2021 and 2022, over 44 million mental health-related meds, largely anti-depressants, were dispensed. While traditional treatments are only about 20 to 30% effective in treating anxiety and depression, recreational cannabis company Melodiol
Read MorePublic
Incannex set to start psychedelic-assisted PTSD treatment in September after TGA approval
Health experts in Australia believe that around 12% of Australians will experience PTSD (post-traumatic stress disorder) at some point in their lives, and about 1.5% of the population, i.e. almost 390,000 people, currently have a PTSD diagnosis. Certain groups, like those in the defence force, military veterans, first responders, and some minority communities, are more
Read MorePublic
Emyria recruits first patient for its meth-assisted therapy to treat PTSD
As news of billionaire (and controversial) business magnate Elon Musk taking “microdoses of ketamine (a dissociative drug)” to manage depression started doing the rounds, a bunch of divisive arguments popped up—is that just an excuse to justify the use of drugs or is there some hidden potential there? Biotech company Emyria (ASX: EMD) makes a
Read MorePublic
- 1
- 2
